Literature DB >> 8293523

The stability of a novel carbapenem antibiotic, meropenem (SM-7338), in a solid state formulation for injection.

Y Takeuchi1, Y Takebayashi, M Sunagawa, Y Isobe, Y Hamazume, A Uemura, T Noguchi.   

Abstract

A formulation of meropenem, a novel carbapenem antibiotic for injection, was developed as a vial filled with a mixture of meropenem and dried sodium carbonate. During the design phase, we studied the effect of water in the formulation on the stability of meropenem in the solid state. Meropenem is obtained as trihydrate, whose moisture content is 12.35% and is nonhygroscopic. Dehydrated meropenem, whose moisture content was 3.4%, took up moisture quickly even under low humidity (33% RH). Also, the chemical stability of dehydrated meropenem was poor compared with that of untreated meropenem, which is quite stable. Degradation of meropenem by free water was considered as a possible cause of the poor stability. Degradation of meropenem due to liberation of its crystal water to free water was also observed when meropenem was micronized by pneumatic pulverization. Crystal water of meropenem was found to stay bound and to be almost inert in the formulation. Thus, meropenem injection formulation is stable for long time at room temperature.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8293523     DOI: 10.1248/cpb.41.1998

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  2 in total

1.  Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis.

Authors:  Pankaj Kumar; Amit Kaushik; Drew T Bell; Varsha Chauhan; Fangfang Xia; Rick L Stevens; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

2.  Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy.

Authors:  Julia Langgartner; Antje Vasold; Thomas Glück; Michel Reng; Frieder Kees
Journal:  Intensive Care Med       Date:  2008-02-23       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.